Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 324

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 324
---
$5,815 $2,794 Complementary modulator programs1,532 1,253 279 Unallocated research and development expenses:IPR&D acquisition related costs— 13,639 (13,639)Personnel-related (including stock-based compensation)3,886 2,339 1,547 Other R&D related costs1,377 869 508 Facility, lab and depreciation640 667 (27)Total research and development expenses$16,044 $24,582 $(8,538)

(1)NBD1 and combination development program costs include NBD1 stabilizer activities and development of our proprietary combination therapy. Complementary modulator program costs include manufacturing expenses for the complementary modulators.

Research and development expenses decreased by $8.5 million to $16.0 million for the three months ended September 30, 2025, from $24.6 million for the three months ended September 30, 2024. The decrease in research and development expenses was primarily due to:

•direct research and development expenses increased by $3.1 million primarily due to an increase in clinical programs and combination development activities; and

•unallocated research and development expenses decreased by $11.6 million primarily due to IPR&D acquisition costs incurred in connection with our license agreement with AbbVie of $13.6 million in the third quarter of 2024, partially offset by a $1.5 million increase in personnel-related expenses including stock-based compensation, driven by an increase in the size of our workforce to support our clinical pipeline. 

20

General and Administrative Expenses

The following table summarizes our general and administrative expenses (in thousands):

Three Months Ended September 30,Change20252024Personnel-related (including stock-based compensation)$5,192 $2,197 $2,995 Professional services & fees2,049 817 1,232 Facility and depreciation520 388 132 Total general and administrative expenses$7,761 $3,402 $4,359 

General and administrative expenses increased by $4.4 million to $7.8 million for the three months ended September 30, 2025, from $3.4 million for the three months ended September 30, 2024. The increase in general and administrative expenses was primarily due to:

•$3.0 million increase in personnel-related expenses including stock-based compensation, driven by an increase in the